First-in-Human Implantations of the NaviGate Bioprosthesis in a Severely Dilated Tricuspid Annulus and in a Failed Tricuspid Annuloplasty Ring
2017; Lippincott Williams & Wilkins; Volume: 10; Issue: 12 Linguagem: Inglês
10.1161/circinterventions.117.005840
ISSN1941-7632
AutoresJosé Navia, Samir Kapadia, Haytham Elgharably, Serge C. Harb, Amar Krishnaswamy, Shinya Unai, Stephanie Mick, Leonardo Rodríguez, Donald Hammer, A. Marc Gillinov, Lars G. Svensson,
Tópico(s)Aortic Disease and Treatment Approaches
ResumoHomeCirculation: Cardiovascular InterventionsVol. 10, No. 12First-in-Human Implantations of the NaviGate Bioprosthesis in a Severely Dilated Tricuspid Annulus and in a Failed Tricuspid Annuloplasty Ring Free AccessCase ReportPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCase ReportPDF/EPUBFirst-in-Human Implantations of the NaviGate Bioprosthesis in a Severely Dilated Tricuspid Annulus and in a Failed Tricuspid Annuloplasty Ring Jose L. Navia, MD;, Samir Kapadia, MD;, Haytham Elgharably, MD;, Serge C. Harb, MD;, Amar Krishnaswamy, MD;, Shinya Unai, MD;, Stephanie Mick, MD;, Leonardo Rodriguez, MD;, Donald Hammer, MD;, A. Marc Gillinov, MD; and Lars G. Svensson, MD Jose L. NaviaJose L. Navia From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Samir KapadiaSamir Kapadia From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Haytham ElgharablyHaytham Elgharably From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Serge C. HarbSerge C. Harb From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Amar KrishnaswamyAmar Krishnaswamy From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Shinya UnaiShinya Unai From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Stephanie MickStephanie Mick From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Leonardo RodriguezLeonardo Rodriguez From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , Donald HammerDonald Hammer From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. , A. Marc GillinovA. Marc Gillinov From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. and Lars G. SvenssonLars G. Svensson From the Departments of Thoracic and Cardiovascular Surgery (J.L.N., H.E., S.U., S.M., A.M.G., L.G.S.) and Cardiovascular Medicine (S.K., S.C.H., A.K., L.R., D.H.), Cleveland Clinic, OH. Originally published15 Dec 2017https://doi.org/10.1161/CIRCINTERVENTIONS.117.005840Circulation: Cardiovascular Interventions. 2017;10:e005840IntroductionBased on an old misconception that the tricuspid valve is not important for cardiac performance, functional tricuspid regurgitation (TR) has been historically ignored. As a consequence, an increasing number of patients present in the current era with severe TR associated with right heart failure that is refractory to medical treatment. Traditional or redotricuspid valve surgery in that setting has been shown to have high mortality (up to 35% at 30 days).1–3 Thereby, transcatheter valve implantation technology seems as an attractive alternative. Herein, we report the first-in-human successful implantation of the NaviGate valved-stent (NaviGate Cardiac Structures, Inc, NCSI, Lake Forest, CA) in 2 patients with severe TR and prohibitive risk for conventional surgery, for which they received Food and Drug Administration and institutional review board approvals for compassionate use (Figure 1).Download figureDownload PowerPointFigure 1. The NaviGate valved-stent. A, Ventricular view. B, Lateral view.Case 1A 64-year-old woman presented after multiple admissions for refractory right heart failure with severe functional TR secondary to annular dilatation, severe right ventricular (RV) dysfunction, severe pulmonary hypertension (systolic pressure, 75 mm Hg), and moderate ischemic mitral regurgitation (Figure 2A). Other comorbidities included chronic kidney dysfunction, chest radiation for breast cancer, atrial fibrillation, obstructive lung disease, and coronary bypass surgery with patent grafts. The patient was deemed high risk for conventional open-heart surgery by the Multidisciplinary Heart Team and was found a candidate for compassionate use of a first-in-human NaviGate valved-stent implantation. Preoperative sizing included a focused 4-dimensional computed tomography that was used to develop a 3-dimensional printing model of the right heart structures to simulate the implantation steps of the NaviGate device (Figure 3A–3C). The tricuspid annulus (TA) measured 50×40 mm on the computed tomographic scan.Download figureDownload PowerPointFigure 2. Severe tricuspid regurgitation on preoperative transthoracic echocardiogram. A, Patient #1; B, Patient #2.Download figureDownload PowerPointFigure 3. Preoperative testing in 3-dimensional (3D) printed model. Mimics (Materialise) software used to create the frame of the 3D printed model based on preoperative computed tomography scan (A, patient #1; B, patient #2), 3D printed model of the right heart structures (B, patient #1; E, patient #2), and successful implantation of NaviGate valved-stent (C, patient #1; F, patient #2). AL indicates anterior leaflet; CS, coronary sinus; IVC, inferior vena cava; PL, posterior leaflet; RA, right atrium; RCA, right coronary artery; RV, right ventricle; SL, septal leaflet; SVC, superior vena cava; and SVG, saphenous vein graft.The patient underwent the implantation procedure in a hybrid operating room under fluoroscopy, transesophageal, and intracardiac echocardiographic guidance. We used intracardiac echocardiography to ensure coaxial alignment of the valved-stent to the TA plane before deployment. Transatrial access was obtained via anterolateral mini-thoracotomy using Seldinger technique, and then the delivery system mounted with the valved stent was advanced to the center of the TA. The NaviGate valved-stent (48 mm) was deployed on beating heart without rapid ventricle pacing (Figure 4). Intraoperative transesophageal chocardiography showed functioning bioprosthesis with interval improvement of severe TR to moderate paravalvular leak at the level of the septal leaflet (Figure 5).Download figureDownload PowerPointFigure 4. Fluoroscopy images of transatrial implantation of the NaviGate valved-stent in patient #1. A, Right coronary angiogram as an anatomic landmark to identify the tricuspid annuls. B, Successful deployment of the NaviGate valved-stent in the tricuspid valve.Download figureDownload PowerPointFigure 5. A and B, Postdeployment transesophageal echocardiogram showing mild to moderate paravalvular tricuspid regurgitation.The patient was extubated on postoperative day (POD#) 8, transferred to a ward on POD#17, and discharged home on POD#29. A predischarge echocardiogram showed moderate to severe RV dysfunction and mild to moderate paravalvular TR. She had functional improvement at 5 months; however, she was admitted to the hospital 6 months after surgery for ischemic colitis (unrelated to the procedure) and underwent right hemicolectomy complicated by sepsis and subsequently died.Case 2A 78-year-old man presented with progressive congestive heart failure refractory to optimal medical therapy. He has a history of 3 open-heart surgeries for coronary bypass (patent grafts), mitral valve repair with annuloplasty ring, and 2 tricuspid valve repairs (annuloplasty ring 34 mm). An echocardiogram showed left ventricular ejection fraction 45%, severe pulmonary hypertension (systolic pressure 90 mm Hg), severe RV dysfunction, severe TR because of leaflets tethering, and mild functional mitral regurgitation (Figure 2B). Other comorbidities included diabetes mellitus, atrial fibrillation, obstructive lung disease, and chronic kidney disease. The patient was deemed high risk for conventional open-heart surgery by the Multidisciplinary Heart Team and was found as a candidate for compassionate use of catheter-delivered NaviGate valved-stent. Preoperative planning included testing in a 3-dimensional printing model (Figure 3D–3F).Percutaneous transjugular access was obtained with placement of 42F introducer sheath. The NaviGate valved-stent (36 mm) was positioned at the center of the tricuspid annuloplasty ring and then deployed in a controlled release fashion on beating heart (Figure 6A and 6B). The vascular access was secured with a Perclose device, and then skin incision was closed (Figure 6C). Intraoperative transesophageal chocardiography showed interval improvement of severe TR to mild paravalvular leak (Figure 7). The patient was extubated on the day of surgery, transferred to the ward on POD#2, and was discharged home on POD#7 after an uneventful postoperative course. Predischarge echocardiogram showed severe RV dysfunction and mild paravalvular TR. He is 3 months out from the procedure with functional improvement, stable mild paravalvular TR, and interval improvement of RV function on a follow-up echocardiogram.Download figureDownload PowerPointFigure 6. Fluoroscopy images of transjugular implantation of the NaviGate valved-stent in patient #2. A, Advancing the delivery device across the previous tricuspid annuloplasty ring. B, Successful deployment of the NaviGate valved-stent in the tricuspid valve. C, Neck stab incision.Download figureDownload PowerPointFigure 7. A and B, Postdeployment transesophageal echocardiogram showing mild paravalvular tricuspid regurgitation.CommentThe Heart Team at our institution applies the following criteria to identify candidates for transcatheter tricuspid valve implantation: severe symptomatic TR, prohibitive surgical risk (multiple comorbidities, complicated reoperation, severe RV dysfunction), pulmonary artery pressure ≤90 mm Hg (by echocardiography and right heart catheterization), and the appropriate TA or ring size assessed on focused 4-dimensional computed tomographic scan (available NaviGate valved-stent sizes: 36, 40, 44, 48, and 52 mm). The successful implantation of the NaviGate valved-stent in both patients resulted in interval improvement of the degree of TR, however with residual paravalvular leak. Achieving a complete seal was more challenging in the first patient with severely dilated native TA compared with the second patient with the annuoplasty ring. Another technical challenge is the long angulation part of the current delivery system which limited a perfect coaxial alignment of the valved-stent in the TA. Modifications are being currently ongoing to shorten the distal angulation part of the delivery system. We prefer to oversize the device by 5% to 10% to the TA or the prior ring size to achieve better sealing. Neither of the 2 patients had conduction disturbances or coronary obstruction after the procedure (Figure 8). We use computed tomographic scan to examine the vascular anatomy before surgery, and we do not use venous access with diameter <15 mm. Anticoagulation regimen for the Navigate valved-stent is aspirin and warfarin.Download figureDownload PowerPointFigure 8. Postoperative focused 4-dimensional computed tomography showing the NaviGate valved-stent well seated in the tricuspid annulus and the anatomic relation with surrounding structures (cephalo-caudal orientation). Ao indicates aortic root; LA, left atrium; RCA, right coronary artery; and SVG, saphenous vein graft.The short-term results suggest that the procedure is safe and feasible using transatrial or transjugular approaches on beating heart. Significant reduction of the degree of TR could help improve the clinical status with concurrent medical therapy. Further developments in the current technology will help to achieve optimal results.DisclosuresDr Navia is the inventor on patents related to this device and is a consultant to the company. The other authors report no conflicts.FootnotesCorrespondence to José L. Navia, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Ave/Desk J4-1, Cleveland, OH 44143. E-mail [email protected]References1. Bernal JM, Morales D, Revuelta C, Llorca J, Gutiérrez-Morlote J, Revuelta JM. Reoperations after tricuspid valve repair.J Thorac Cardiovasc Surg. 2005; 130:498–503. doi: 10.1016/j.jtcvs.2004.12.044.CrossrefMedlineGoogle Scholar2. Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome.Eur J Cardiothorac Surg. 2008; 34:402–409; discussion 409. doi: 10.1016/j.ejcts.2008.05.006.CrossrefMedlineGoogle Scholar3. Bouleti C, Juliard JM, Himbert D, Iung B, Brochet E, Urena M, Dilly MP, Ou P, Nataf P, Vahanian A. Tricuspid valve and percutaneous approach: no longer the forgotten valve!Arch Cardiovasc Dis. 2016; 109:55–66. doi: 10.1016/j.acvd.2015.08.002.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hahn R, Badano L, Bartko P, Muraru D, Maisano F, Zamorano J and Donal E (2022) Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome, European Heart Journal - Cardiovascular Imaging, 10.1093/ehjci/jeac009, 23:7, (913-929), Online publication date: 21-Jun-2022. Vogelhuber J, Weber M and Nickenig G (2021) Transcatheter tricuspid intervention: ready for primetime?, Heart, 10.1136/heartjnl-2020-316578, 108:6, (479-491), Online publication date: 1-Mar-2022. Barry O, Bouhout I, Kodali S, George I, Rosenbaum M, Petit C and Kalfa D (2022) Interventions for Congenital Atrioventricular Valve Dysfunction, Journal of the American College of Cardiology, 10.1016/j.jacc.2021.08.083, 79:22, (2259-2269), Online publication date: 1-Jun-2022. Uppal S, Bossory L, Biersmith M and Harfi T (2022) Computed Tomography Assessment of the Tricuspid Valve and the Right Heart Tricuspid Valve Disease, 10.1007/978-3-030-92046-3_7, (93-110), . Kresoja K, Rahgozar K, Kitamura M, Goldberg Y, Latib A and Lurz P (2022) Transcatheter Tricuspid Valve Repair and Replacement Interventional Cardiology, 10.1002/9781119697367.ch66, (677-684), Online publication date: 3-Jun-2022. Komlev A, Saidova M, Imaev T and Akchurin R (2022) Diagnosis and transcatheter treatment of tricuspid regurgitation, Kardiologicheskii vestnik, 10.17116/Cardiobulletin2022170215, 17:2, (5), . Tadic M, Cuspidi C, Morris D and Rottbauer W (2021) Functional tricuspid regurgitation, related right heart remodeling, and available treatment options: good news for patients with heart failure?, Heart Failure Reviews, 10.1007/s10741-021-10141-6, 27:4, (1301-1312), Online publication date: 1-Jul-2022. Mangieri A, Laricchia A, Cereda A, Khokhar A, Regazzoli D, Giannini F, Reimers B and Colombo A (2021) Diagnosis and Management of Failed Surgical Tricuspid Valve Annuloplasty, Current Cardiology Reports, 10.1007/s11886-021-01569-1, 23:10, Online publication date: 1-Oct-2021. Sun Z, Li H, Zhang Z, Li Y, Zhang L, Xie Y, Han Z, Wang J, Chen Y, Yang Y, Lv Q and Xie M (2021) Twelve-month outcomes of the LuX-Valve for transcatheter treatment of severe tricuspid regurgitation, EuroIntervention, 10.4244/EIJ-D-21-00095, 17:10, (818-826), Online publication date: 1-Nov-2021. Yandrapalli S and Kolte D (2021) Tricuspid Regurgitation: When and How to Treat, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-021-00938-x, 23:9, Online publication date: 1-Sep-2021. Praz F, Muraru D, Kreidel F, Lurz P, Hahn R, Delgado V, Senni M, von Bardeleben R, Nickenig G, Hausleiter J, Mangieri A, Zamorano J, Prendergast B and Maisano F (2021) Transcatheter treatment for tricuspid valve disease, EuroIntervention, 10.4244/EIJ-D-21-00695, 17:10, (791-808), Online publication date: 1-Nov-2021. Muntané-Carol G, Alperi A, Faroux L, Bédard E, Philippon F, Dagenais F and Rodés-Cabau J (2021) Transcatheter Interventions for Tricuspid Valve Disease: What to Do and Who to Do It On, Canadian Journal of Cardiology, 10.1016/j.cjca.2020.12.029, 37:7, (953-967), Online publication date: 1-Jul-2021. Mesnier J, Alperi A, Panagides V, Bédard E, Salaun E, Philippon F and Rodés-Cabau J (2021) Transcatheter tricuspid valve interventions: Current devices and associated evidence, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2021.11.007, 69, (89-100), Online publication date: 1-Nov-2021. Aoi S, Wiley J, Ho E, Goldberg Y, Chau M and Latib A (2021) Transcatheter tricuspid valve implantation with the Cardiovalve system, Future Cardiology, 10.2217/fca-2020-0181, 17:6, (963-969), Online publication date: 1-Sep-2021. Ben Ali W, Ruf T, Perrin N, Bouhout I, Fam N, Kresoja K, Lurz P, Stephan von Bardeleben R, Modine T and Ibrahim R (2021) Indications, Limitations, and Development of Tricuspid Valve Interventions in Adults, Canadian Journal of Cardiology, 10.1016/j.cjca.2021.08.013, Online publication date: 1-Aug-2021. Lu F, An Z, Ma Y, Song Z, Cai C, Li B, Zhou G, Han L, Wang J, Bai Y, Liu X, Wang J, Meng X, Zhang H, Yang J, Dong N, Hu S, Pan X, Cheung A, Qiao F and Xu Z (2021) Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation, Heart, 10.1136/heartjnl-2020-318199, 107:20, (1664-1670), Online publication date: 1-Oct-2021. Fam N, von Bardeleben R, Hensey M, Kodali S, Smith R, Hausleiter J, Ong G, Boone R, Ruf T, George I, Szerlip M, Näbauer M, Ali F, Moss R, Bapat V, Schnitzler K, Kreidel F, Ye J, Deva D, Mack M, Grayburn P, Peterson M, Leon M, Hahn R and Webb J (2021) Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2020.11.045, 14:5, (501-511), Online publication date: 1-Mar-2021. Cammalleri V, Mega S, Ussia G and Grigioni F (2021) Mitral and Tricuspid Valves Percutaneous Repair in Patients with Advanced Heart Failure, Heart Failure Clinics, 10.1016/j.hfc.2021.05.006, 17:4, (607-618), Online publication date: 1-Oct-2021. Cesna S and Eicken A (2020) Percutaneous techniques for treatment of tricuspid valve dysfunction in congenital heart disease – an emerging therapy, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2021.1865154, 19:9, (817-824), Online publication date: 2-Sep-2021. Elgharably H, Javadikasgari H, Koprivanac M, Lowry A, Sato K, Blackstone E, Klein A, Gillinov A, Svensson L and Navia J (2020) Right versus left heart reverse remodelling after treating ischaemic mitral and tricuspid regurgitation, European Journal of Cardio-Thoracic Surgery, 10.1093/ejcts/ezaa326, 59:2, (442-450), Online publication date: 29-Jan-2021. Alushi B, Vathie K, Thiele H and Lauten A (2020) Transcatheter therapies for severe tricuspid regurgitation. Quo vadis?Kathetergestützte Therapie bei hochgradiger Trikuspidalklappeninsuffizienz. Quo vadis?, Herz, 10.1007/s00059-020-04941-z, 46:3, (234-241), Online publication date: 1-Jun-2021. Pozzoli A, Taramasso M, Vicentini L, Gavazzoni M, Miura M, Russo G, Gülmez G, Ferrari E, Sromicki J, Balcova J, Riva M, Zuber M and Maisano F (2021) Transcatheter Tricuspid Valve Replacement, Operative Techniques in Thoracic and Cardiovascular Surgery, 10.1053/j.optechstcvs.2021.06.003, 26:3, (376-406), Online publication date: 1-Nov-2022. Fam N, Ong G, Deva D and Peterson M (2020) Transfemoral Transcatheter Tricuspid Valve Replacement, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2020.01.194, 13:10, (e93-e94), Online publication date: 1-May-2020. Donatelle M and Ailawadi G (2020) Transcatheter tricuspid valve repair: Bringing the forgotten valve into the spotlight, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2020.04.184, 160:6, (1467-1473), Online publication date: 1-Dec-2020. Hamid N and Hahn R (2020) Transcatheter treatments for tricuspid valve diseases Emerging Technologies for Heart Diseases, 10.1016/B978-0-12-813706-2.00023-3, (483-502), . Ali A, Ballard D, Althobaity W, Christensen A, Geritano M, Ho M, Liacouras P, Matsumoto J, Morris J, Ryan J, Shorti R, Wake N, Rybicki F and Sheikh A (2020) Clinical situations for which 3D printing is considered an appropriate representation or extension of data contained in a medical imaging examination: adult cardiac conditions, 3D Printing in Medicine, 10.1186/s41205-020-00078-1, 6:1, Online publication date: 1-Dec-2020. Chung C and George I (2020) Emerging transcatheter therapies for tricuspid valve disease, JTCVS Open, 10.1016/j.xjon.2020.04.003, 2, (14-19), Online publication date: 1-Jun-2020. Nagaraja V, Kapadia S, Miyasaka R, Harb S and Krishnaswamy A (2020) Contemporary review of percutaneous therapy for tricuspid valve regurgitation, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2020.1750370, 18:4, (209-218), Online publication date: 2-Apr-2020. Sudhakar B (2020) Evaluation and Management of Primary Tricuspid Regurgitation, Indian Journal of Clinical Cardiology, 10.1177/2632463620954091, 1:3-4, (174-185), Online publication date: 1-Dec-2020. Chang C, Veen K, Hahn R, Bogers A, Latib A, Oei F, Abdelghani M, Modolo R, Ho S, Abdel-Wahab M, Fattouch K, Bosmans J, Caliskan K, Taramasso M, Serruys P, Bax J, van Mieghem N, Takkenberg J, Lurz P, Modine T and Soliman O (2019) Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review, European Heart Journal, 10.1093/eurheartj/ehz614, 41:20, (1932-1940), Online publication date: 21-May-2020. Löw K, Hausleiter J and Braun D (2020) Interventionelle Therapien zur Behandlung der hochgradigen Trikuspidalklappeninsuffizienz, Der Klinikarzt, 10.1055/a-1236-7142, 49:09, (358-362), Online publication date: 1-Sep-2020. Lu F, Qiao F, Lv Y, An Z, Liu X, Cao P, Song Z and Xu Z (2020) A radial force-independent bioprosthesis for transcatheter tricuspid valve implantation in a preclinical model, International Journal of Cardiology, 10.1016/j.ijcard.2020.06.070, 319, (120-126), Online publication date: 1-Nov-2020. Overtchouk P, Piazza N, Granada J, Soliman O, Prendergast B and Modine T (2020) Advances in transcatheter mitral and tricuspid therapies, BMC Cardiovascular Disorders, 10.1186/s12872-019-01312-3, 20:1, Online publication date: 1-Dec-2020. Weber M (2020) Interventionelle Therapie der Trikuspidalklappeninsuffizienz, CardioVasc, 10.1007/s15027-020-2156-2, 20:4, (35-38), Online publication date: 1-Sep-2020. Hahn R, Kodali S, Fam N, Bapat V, Bartus K, Rodés-Cabau J, Dagenais F, Estevez-Loureiro R, Forteza A, Kapadia S, Latib A, Maisano F, McCarthy P, Navia J, Ong G, Peterson M, Petrossian G, Pozzoli A, Reinartz M, Ricciardi M, Robinson N, Sievert H, Taramasso M, Agarwal V, Bédard E, Tarantini G and Colli A (2020) Early Multinational Experience of Transcatheter Tricuspid Valve Replacement for Treating Severe Tricuspid Regurgitation, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2020.07.008, 13:21, (2482-2493), Online publication date: 1-Nov-2020. Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly K, Denti P, Deuschl F, Englmeier A, Fam N, Frerker C, Hausleiter J, Himbert D, Ho E, Juliard J, Kaple R, Kreidel F, Kuck K, Ancona M, Lauten A, Lurz P, Mehr M, Nazif T, Nickening G, Pedrazzini G, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Sievert K, Tang G, Tanner F, Vahanian A, Webb J, Windecker S, Yzeiray E, Zuber M, Maisano F, Leon M and Hahn R (2019) Outcomes After Current Transcatheter Tricuspid Valve Intervention, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2018.10.022, 12:2, (155-165), Online publication date: 1-Jan-2019. Kolte D and Elmariah S (2019) Transcatheter Tricuspid Valve Therapy, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-019-0730-7, 21:6, Online publication date: 1-Jun-2019. Gavazzoni M, Pozzoli A, Zuber M, Ho E, Tanner F, Kapos I, Miura M, Vicentini L, Maisano F and Taramasso M (2019) Single-Center Experience With Catheter-Based Tricuspid Valve Replacement for Tricuspid Regurgitation, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2018.11.017, 12:4, (749-750), Online publication date: 1-Apr-2019. Elgharably H, Harb S, Kapadia S, Svensson L and Navia J (2019) Transcatheter innovations in tricuspid regurgitation: Navigate, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2019.11.004, 62:6, (493-495), Online publication date: 1-Nov-2019. Miura M, Maisano F, Zuber M, Gavazzoni M, Cuevas O, Lin S, Ho E, Pozzoli A and Taramasso M Novel transcatheter therapies for treating tricuspid regurgitation, Minerva Cardioangiologica, 10.23736/S0026-4725.18.04837-5, 67:3 Asmarats L, Taramasso M and Rodés-Cabau J (2019) Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field, Nature Reviews Cardiology, 10.1038/s41569-019-0186-1, 16:9, (538-554), Online publication date: 1-Sep-2019. El Hajj S and Eleid M (2019) Transcatheter Mitral Valve Replacement: An Update on the Current Literature, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-019-0734-3, 21:7, Online publication date: 1-Jul-2019. Mehta A, Sale S, Navia J, Kapadia S, Krishnaswamy A and Alfirevic A (2019) Anesthetic and Procedural Considerations for Patients Undergoing Tricuspid Valve Replacement with NaviGate Valved Stent, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2018.09.024, 33:7, (1991-1994), Online publication date: 1-Jul-2019. Ho E, Ong G and Fam N (2019) Transcatheter tricuspid valve intervention, Current Opinion in Cardiology, 10.1097/HCO.0000000000000607, 34:2, (164-172), Online publication date: 1-Mar-2019. Voci D, Pozzoli A, Miura M, Gavazzoni M, Gülmez G, Scianna S, Zuber M, Maisano F and Taramasso M (2019) Developments in transcatheter tricuspid valve therapies, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2019.1699056, 17:12, (841-856), Online publication date: 2-Dec-2019. Curio J, Demir O, Pagnesi M, Mangieri A, Giannini F, Weisz G and Latib A (2019) Update on the Current Landscape of Transcatheter Options for Tricuspid Regurgitation Treatment, Interventional Cardiology Review, 10.15420/icr.2019.5.1, 14:2, (54-61) Lau R, Fishbein G and Fishbein M (2019) Specific Anatomic Considerations for Tricuspid Interventions, Current Cardiology Reports, 10.1007/s11886-019-1141-9, 21:7, Online publication date: 1-Jul-2019. Asmarats L, Dagenais F, Bédard E, Pasian S, Hahn R, Navia J and Rodés-Cabau J (2018) Transcatheter Tricuspid Valve Replacement for Treating Severe Tricuspid Regurgitation: Initial Experience With the NaviGate Bioprosthesis, Canadian Journal of Cardiology, 10.1016/j.cjca.2018.07.481, 34:10, (1370.e5-1370.e7), Online publication date: 1-Oct-2018. Kim S, Singh H, Nati J and Ginns J (2018) Multi-Modality Imaging in the Evaluation and Treatment of Tricuspid Regurgitation, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-018-0672-5, 20:9, Online publication date: 1-Sep-2018. Asmarats L, Puri R, Latib A, Navia J and Rodés-Cabau J (2018) Transcatheter Tricuspid Valve Interventions, Journal of the American College of Cardiology, 10.1016/j.jacc.2018.04.031, 71:25, (2935-2956), Online publication date: 1-Jun-2018. Colli A, Gerosa G, Bartus K and Tarantini G (2018) Transcatheter tricuspid valve replacement with a self-expanding bioprosthesis, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2018.03.096, 156:3, (1064-1066), Online publication date: 1-Sep-2018. Atianzar K, Zhang M and Gafoor S Percutaneous tricuspid valve replacement: orthotopic and heterotopic valves, Minerva Cardioangiologica, 10.23736/S0026-4725.18.04659-5, 66:6 Regazzoli D, Mangieri A, Demir O, Ancona M, Lanzillo G, Giannini F, Leone P, Colombo A and Latib A The future of percutaneous tricuspid valve interventions, Minerva Cardioangiologica, 10.23736/S0026-4725.18.04757-6, 66:6 Navia J, Kapadia S, Elgharably H, Maluenda G, Bartuś K, Baeza C, Nair R, Rodés-Cabau J, Beghi C and Quijano R (2018) Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model, JACC: Basic to Translational Science, 10.1016/j.jacbts.2017.08.003, 3:1, (67-79), Online publication date: 1-Feb-2018. Beckhoff F, Alushi B, Jung C, Navarese E, Franz M, Kretzschmar D, Wernly B, Lichtenauer M and Lauten A (2018) Tricuspid Regurgitation – Medical Management and Evolving Interventional Concepts, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00049, 5 Reineke D, Roost E, Schoenhoff F, Pasic M, Kadner A, Englberger L and Carrel T (2018) Transcatheter Treatment of Tricuspid Valve Disease: An Unmet Need? The Surgical Point of View, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00098, 5 Demir O, Regazzoli D, Mangieri A, Ancona M, Mitomo S, Weisz G, Colombo A and Latib A (2018) Transcatheter Tricuspid Valve Replacement: Principles and Design, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00129, 5 Laricchia A, Khokhar A and Giannini F (2020) New Percutaneous Options for Tricuspid Intervention: How to Identify the Good Clinical Candidate, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.583307, 7 Simard T and Eleid M (2021) Transcatheter Tricuspid Valve Intervention: Current Perspective, US Cardiology Review, 10.15420/usc.2020.26, 15 Fam N, Eckstein J, Gandhi S and Peterson M (2019) Transcatheter tricuspid valve replacement for pacemaker-associated tricuspid regurgitation, EuroIntervention, 10.4244/EIJ-D-18-00970, 14:15, (e1556-e1557) Cammalleri V, Carpenito M, Bono M, Mega S, Ussia G and Grigioni F (2021) Transcatheter Tricuspid Valve Therapy: From Anatomy to Intervention, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.778445, 8 Mangieri A, Pagnesi M, Regazzoli D, Laricchia A, Ho E, Goldberg Y, Chau M, Gallo F, Fisicaro A, Khokhar A, Colombo A, Giannini F and Latib A (2020) Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.581211, 7 Gheorghe L, Brouwer J, Wang D, Wunderlich N, Rana B, Rensing B, Eefting F, Timmers L and Swaans M (2020) Current Devices in Mitral Valve Replacement and Their Potential Complications, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.531843, 7 Goldberg Y, Ho E, Chau M and Latib A (2021) Update on Transcatheter Tricuspid Valve Replacement Therapies, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.619558, 8 Vahanian A, Brochet E and Juliard J (2018) "Guidelines Recommendations on the Treatment of Tricuspid Regurgitation. Where Are We and Where Do We Go With Transcatheter Valve Intervention", Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2018.00037, 5 Winkel M, Brugger N, Khalique O, Gräni C, Huber A, Pilgrim T, Billinger M, Windecker S, Hahn R and Praz F (2020) Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.00060, 7 December 2017Vol 10, Issue 12 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCINTERVENTIONS.117.005840PMID: 29246915 Originally publishedDecember 15, 2017 Keywordsthoracotomyblood pressuretricuspid valveheart failurebioprosthesisPDF download Advertisement SubjectsCatheter-Based Coronary and Valvular InterventionsEchocardiographyStentValvular Heart DiseaseVascular Disease
Referência(s)